Sophie Hallakou-Bozec
Inventor
Stats
- 11 US patents issued
- 19 US Applications filed
- most recent filing
This is official USPTO record data
Details
- 11 US Patents Issued
- 19 US Applications Filed
- 58 Total Citation Count
- Apr 2, 2021 Most Recent Filing
- Jul 3, 2006 Earliest Filing
Work History
Patent Owner | Applications Filed | Year |
---|---|---|
EDELRIS | 2
| 2014
|
ENS - ECOLE NORMALE SUPÉRIEURE DE LYON | 2
| 2014
|
MERCK PATENT GMBH | 1
2 2 6 2 | 2006
2007 2008 2009 2012 |
POXEL | 2
2 3 2 2 | 2009
2010 2011 2013 2014 |
UNIVERSITE CLAUDE BERNARD LYON 1 | 2
| 2014
|
UNIVERSITÉ CLAUDE BERNARD—LYON 1 | 1
| 2014
|
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE | 2
| 2014
|
ENS—ECOLE NORMALE SUPÉRIEURE DE LYON | 1
| 2014
|
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) | 2
| 2014
|
Inventor Addresses
Address | Duration |
---|---|
ANTONY, FR | Aug 04, 16 - May 18, 23 |
Antony, FR | Jun 18, 15 - Dec 26, 23 |
Montrouge, FR | Apr 23, 09 - Jun 14, 16 |
Technology Profile
Technology | Matters | |
---|---|---|
A01N: | PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF | 2 |
A61K: | PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES | 17 |
A61P: | THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS | 13 |
Patents / Publication
Patents / Publication # | Year of Publication / Issued | Title | Citations |
---|---|---|---|
11850238 | 2023 | Use of a thienopyridone derivative in the treatment of adrenoleukodystrophy or adrenomyeloneuropathy | 0 |
2023/0149,370 | 2023 | USE OF A THIENOPYRIDONE DERIVATIVE IN THE TREATMENT OF DIABETIC NEPHROPATHY | 1 |
2023/0120,204 | 2023 | USE OF A THIENOPYRIDONE DERIVATIVE IN THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) | 1 |
2023/0112,080 | 2023 | USE OF A THIENOPYRIDONE DERIVATIVE IN THE TREATMENT OF ADRENOLEUKODYSTROPHY OR ADRENOMYELONEUROPATHY | 0 |
2022/0017,532 | 2022 | MONOHYDRATE POTASSIUM SALT OF A THIENOPYRIDONE DERIVATIVE AND ITS PREPARATION PROCESS | 0 |
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level.
>
Upgrade to our Level for up to -1 portfolios!.